重组人干扰素凝胶联合保妇康栓治疗宫颈高危型HPV感染的临床观察 点击下载
| 论文标题： | 重组人干扰素凝胶联合保妇康栓治疗宫颈高危型HPV感染的临床观察 |
| 英文标题： | |
| 中文摘要： | 目的：探讨重组人干扰素凝胶联合保妇康栓治疗宫颈高危型人乳头瘤病毒（HPV）感染的疗效及安全性。方法：收集2017年8月－2019年9月海南医学院第一附属医院妇科确诊并收治的高危型HPV持续感染患者259例，按照随机数字表法分为干扰素组（82例）、保妇康栓组（86例）及联合组（91例）。干扰素组和保妇康栓组患者分别于睡前给予重组人干扰素α2b凝胶1g，qd或保妇康栓1粒，qd；联合组患者同时给予重组人干扰素α2b凝胶1g和保妇康栓1粒，qd，连续治疗3个月。记录各组患者的临床疗效，HPV转阴时间、异常分泌物持续时间、液基薄层细胞学检查（LCT）结果、宫颈炎症积分、HPV相对光化学值/临界值（RLU/CO）和不良反应发生情况。结果：联合组患者治疗总有效率显著高于干扰素组及保妇康栓组，其HPV转阴时间及异常分泌物持续时间均显著短于干扰素组及保妇康栓组（P＜0.05）。治疗前，3组患者的LCT正常率均为0，宫颈炎症积分和HPVRLU/CO均无显著差异（P＞0.05）；治疗后，3组患者的LCT正常率均显著高于治疗前，且联合组患者显著高于干扰素组及保妇康栓组；3组患者宫颈炎症积分和HPVRLU/CO均显著低于治疗前，且联合组显著低于干扰素组及保妇康栓组（P＜0.05）；而干扰素组与保妇康栓组患者治疗后上述指标组间比较以及各组患者用药期间不良反应总发生率比较，差异均无统计学意义（P＞0.05）。结论：重组人干扰素凝胶联合保妇康栓治疗宫颈高危型HPV感染的疗效显著，且安全性较高。 |
| 英文摘要： | OBJECTIVE：To inv estigate therapeutic efficacy and safety of recombinant human interferon gel combined with Baofukang suppository in the treatment of cervical high-risk human papillomavirus （HPV）infection. METHODS ：Totally 259 patients with persistent high-risk HPV infection diagnosed and treated in gynecology department of the First Affiliated Hospital of Hainan Medical University from Aug. 2017 to Sept. 2019 were selected and divided into interferon group （n＝82），Baofukang suppository group （n＝86）and combination group （n＝91）according to random number table. The patients in interferon group and Baofukang suppository group were given Recombinant human interferon α2b gel 1 g, qd or Baofukang suppository 1 capsule，qd； the patients in combination group were given Recombinant human interferon α2b gel and Baofukang suppository 1 capsule，qd；for 3 months. Then the clinical efficacy ，negative time of HPV ，duration of abnormal secretion ，LCT test results ，cervical inflammation score ，HPV relative light unit/critical value （RLU/CO）and the incidence of ADR were recorded. RESULTS ：The total effective rate of combination group was significantly higher than that of interferon group and Baofukang suppository group ， the negative time of HPV and duration of abnormal secretion in combination group were significantly shorter than interferon group and Baofukang suppository group （P＜0.05）. Before treatment ，the normal rate of LCT of 3 groups were 0，and there was no statistical significance in cervical inflammation score and HPV RLU/CO among 3 groups（P＞0.05）. After treatment ，normal rate of LCT was increased in 3 groups，compared with before treatment （P＜0.05），and normal rate of LCT in combination group was significantly higher than interferon group and Baofukang suppository group. The cervical inflammation score and HPV RLU/CO were significantly lower than before treatment ，and the combination group was significantly lower than interferon group and Baofukang suppository group （P＜0.05）. There was no statistical significance in above indicatora after treatment betwent interferon group and Baofukang suppository group and the incidence of ADR among 3 groups during medication （P＞0.05）. CONCLUSIONS：The application of recombinant human interferon gel combined with Baofukang suppository is effective and safe way in the treatment of cervical high-risk HPV infection. |
| 期刊： | 2020年第31卷第08期 |
| 作者： | 苏小玉，蒙莉萍，邹聪聪，周桔丰，王芳，陈曼玲 |
| 英文作者： | SU Xiaoyu ，MENG Liping ，ZOU Congcong ，ZHOU Jufeng ，WANG Fang，CHEN Manling |
| 关键字： | 重组人干扰素；保妇康栓；宫颈；高危型人乳头瘤病毒；感染；临床观察 |
| KEYWORDS： | Recombinant human interferon ；Baofukang suppository ；Cervix；High-risk HPV ；Infection；Clinical observation |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！